List of Excipients in Branded Drug ADHANSIA XR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Adlon Therapeutics LP	ADHANSIA XR	methylphenidate hydrochloride	72912-525	AMMONIO METHACRYLATE COPOLYMER TYPE B
Adlon Therapeutics LP	ADHANSIA XR	methylphenidate hydrochloride	72912-525	FD&C BLUE NO. 1
Adlon Therapeutics LP	ADHANSIA XR	methylphenidate hydrochloride	72912-525	GLYCERYL MONOSTEARATE

ADHANSIA XR Excipient Strategy and Commercial Opportunities: Formulation, Generic Entry, and CMC Analysis

Last updated: September 5, 2026

ADHANSIA XR is an extended-release methylphenidate hydrochloride capsule built around multiparticulate delivery. Its commercial value is tied less to any single inactive ingredient than to the combined control of immediate-release and extended-release bead populations, coating performance, dose proportionality, and capsule-sprinkling behavior. The product received FDA approval in 2019 but has since had limited commercial availability, creating opportunities for authorized supply, generic development, excipient substitution, and platform licensing.

What is ADHANSIA XR and how does its formulation work?

ADHANSIA XR is a once-daily, orally administered extended-release formulation of methylphenidate hydrochloride for attention-deficit/hyperactivity disorder. It was developed by Adlon Therapeutics, a Purdue-related company, under NDA 211125.[1]

The product is available in 25 mg, 35 mg, 45 mg, 55 mg, 70 mg, and 85 mg strengths. The labeled dosage range is 25 mg to 85 mg once each morning. The capsules may be swallowed whole or opened and sprinkled over applesauce, which makes particle robustness, taste, and dose uniformity commercially relevant.[1]

ADHANSIA XR uses multiparticulate beads with distinct release characteristics:

• An immediate-release fraction produces an early methylphenidate exposure.
• Extended-release beads provide prolonged delivery.
• Polymer-coated particles control drug diffusion and dissolution.
• The capsule format enables administration without requiring the patient to swallow the intact capsule.

The formulation approach is technically different from osmotic tablet systems such as CONCERTA and from simple coated-tablet products. Multiparticulate systems can provide greater flexibility in release design, but they increase manufacturing complexity and impose tighter controls on coating thickness, particle-size distribution, drug loading, and blend uniformity.

What excipients are used in ADHANSIA XR?

The US prescribing information identifies a multiparticulate excipient system that includes sugar spheres, hypromellose, ethylcellulose, povidone, talc, triethyl citrate, dibutyl sebacate, gelatin, titanium dioxide, and capsule colorants.[1]

Excipient or material	Primary formulation role	Commercial relevance
Sugar spheres	Inert cores for drug layering	Requires consistent particle size, friability, and surface morphology
Hypromellose	Film former, binder, or barrier-layer component	Supports drug layering and coating adhesion
Povidone	Binder and processing aid	Affects drug-layer integrity and aqueous or solvent-based coating behavior
Ethylcellulose	Water-insoluble release-controlling polymer	Central to sustained-release performance
Talc	Anti-tacking and processing aid	Controls coating defects and particle agglomeration
Triethyl citrate	Plasticizer	Improves flexibility of polymer films
Dibutyl sebacate	Plasticizer for controlled-release coating	Influences film permeability and mechanical durability
Gelatin	Hard-capsule shell	Affects moisture sensitivity and shell performance
Titanium dioxide and colorants	Capsule appearance and identification	Relevant to regulatory specifications and supply continuity

The product’s excipient strategy is therefore a combination of core-based drug layering, polymer-film control, plasticization, and capsule presentation. Ethylcellulose is likely to be the most strategically important functional excipient because changes in polymer grade, viscosity, particle size, or coating process can alter dissolution and pharmacokinetics.

Which excipients create the largest technical barriers to substitution?

Ethylcellulose and plasticizers create the highest risk of bio-performance changes. A generic or reformulated product cannot assume that replacing one supplier’s ethylcellulose with another’s will preserve the same release profile. Relevant variables include:

• Polymer viscosity and molecular-weight distribution
• Particle size and dispersion
• Degree of substitution
• Coating-solution solids content
• Plasticizer concentration
• Coating weight gain
• Cure time and temperature
• Residual solvent profile
• Film permeability after storage

Sugar spheres also have a disproportionate impact on process performance. Variability in size and surface roughness can change drug-layer uniformity and coating thickness. This can create batch-to-batch differences in dissolution even when the nominal formula remains unchanged.

Povidone grade and concentration affect adhesion during drug layering. Excessive binder can increase agglomeration, while insufficient binder can produce friable particles and potency variability.

Talc is operationally important because inadequate anti-tacking control can cause bead agglomeration during coating. Excessive talc can reduce coating integrity or create variability in the functional polymer film.

What formulation patents and intellectual-property barriers affect ADHANSIA XR?

The primary intellectual-property barrier is the multiparticulate extended-release architecture, rather than the use of common excipients individually. Standard excipients such as hypromellose, talc, povidone, ethylcellulose, and triethyl citrate generally have limited standalone exclusivity value. Protection can arise from claims covering:

• Immediate-release and extended-release methylphenidate populations in the same dosage form
• Specific ratios between release fractions
• Drug-layered inert cores
• Functional polymer coatings
• Dissolution profiles
• Once-daily pharmacokinetic exposure
• Sprinkle administration
• Dose proportionality across capsule strengths
• Manufacturing processes for layered and coated beads

A formulation using the same excipients may still avoid infringement if it uses a materially different release architecture. Conversely, a generic product using different excipients may face risk if its bead structure, release profile, or manufacturing process falls within valid patent claims.

Patent analysis should distinguish three categories:

IP category	Relevance to ADHANSIA XR
Composition patents	May claim the multiparticulate methylphenidate dosage form
Method-of-use patents	May cover treatment of ADHD with specific exposure or dosing schedules
Manufacturing patents	May cover drug layering, coating, curing, or particle assembly

Public patent databases and FDA Orange Book records should be reviewed before relying on any specific expiration date or Paragraph IV conclusion. The Orange Book, rather than marketing materials, is the controlling source for listed patents associated with the approved NDA.[2]

When does ADHANSIA XR lose exclusivity?

ADHANSIA XR received FDA approval in August 2019. FDA regulatory exclusivity and patent exclusivity are separate issues.

The product’s likely five-year new chemical entity exclusivity period would have blocked submission of an ANDA for the same active ingredient until August 2024, unless an applicable exception applied. That regulatory period does not establish the date of generic launch. Launch timing depends on Orange Book-listed patents, litigation, settlements, pediatric exclusivity, and any remaining unexpired claims.[1,2]

Exclusivity element	ADHANSIA XR assessment
FDA approval	2019
Likely NCE exclusivity	Approximately five years from approval
Active ingredient	Methylphenidate hydrochloride
Product type	Small-molecule drug
Biosimilar pathway	Not applicable
Generic pathway	ANDA, subject to reference-product and patent requirements
Orange Book relevance	High
Pediatric exclusivity	Must be confirmed from FDA records
Commercial launch date	Depends on patents, litigation, and product availability

A precise generic-entry date cannot be inferred from the approval date alone. Patent expiration and litigation records must be evaluated at the claim level.

Are there Paragraph IV challenges to ADHANSIA XR?

ADHANSIA XR is eligible for ANDA competition because it is a small-molecule capsule product. A generic applicant could file a Paragraph IV certification against an Orange Book-listed patent, asserting that the patent is invalid, unenforceable, or not infringed.

Potential Paragraph IV targets would include patents claiming:

• The multiparticulate bead arrangement
• Specific release fractions
• Dissolution windows
• Controlled-release coating compositions
• Capsule strengths or dose proportionality
• Methods of treating ADHD with the dosage form

A Paragraph IV filing can trigger a 30-month stay of FDA approval if the patent holder files suit within the statutory period. The commercial effect depends on the number of listed patents, patent expiration dates, claim breadth, and whether the parties settle before trial.[3]

No biosimilar risk applies because methylphenidate is a chemically synthesized active pharmaceutical ingredient. The competitive threat is generic substitution, not biosimilar interchangeability.

What commercial opportunities exist for excipient suppliers?

The most attractive excipient opportunities are functional materials that improve process consistency or provide a non-infringing path to equivalent performance.

Ethylcellulose and alternative release polymers

Suppliers can compete on:

• Narrower viscosity specifications
• Improved aqueous-dispersion stability
• Lower residual solvent burden
• Better film flexibility
• Reduced coating defects
• More consistent permeability after curing

A supplier with a well-characterized ethylcellulose grade could support generic development by demonstrating comparable dissolution across scale-up and stability studies.

Alternative polymers may create a design-around opportunity, but they introduce bioequivalence risk. Replacing ethylcellulose with another release-controlling polymer could require extensive formulation optimization and may produce a different in vitro-in vivo relationship.

Sugar spheres and inert cores

High-quality sugar spheres can reduce variability in:

• Drug-layer thickness
• Bead yield
• Coating weight gain
• Capsule fill weight
• Dissolution

Suppliers that provide tight particle-size distributions, low friability, and reliable compendial compliance can target both the reference-product supply chain and generic manufacturers.

Plasticizers

Triethyl citrate and dibutyl sebacate influence polymer-film flexibility and permeability. Commercial differentiation may come from:

• Lower extractables and leachables
• Better compatibility with aqueous or organic coating systems
• Reduced odor or residual solvent concerns
• Improved coating durability
• Consistent plasticizer distribution

Plasticizer substitution is feasible in principle but requires comparative dissolution, stability, and mechanical testing.

Capsule shells and color systems

Capsule-shell suppliers can compete through:

• Low-moisture gelatin
• Improved shell brittleness performance
• Reliable color matching
• Reduced titanium dioxide dependence where permitted
• Faster supply and regional manufacturing

Because ADHANSIA XR can be opened and sprinkled, shell integrity remains important even if the capsule is not swallowed whole. The shell must protect the bead blend during storage and handling.

What generic development opportunities exist for ADHANSIA XR?

The strongest generic opportunity is a capsule containing a comparable immediate-release and extended-release multiparticulate system. A generic applicant would likely focus on three development routes:

1. Replicate the bead architecture using the listed excipients.
2. Use a modified polymer system that produces equivalent dissolution and pharmacokinetics.
3. Develop a different multiparticulate design that meets FDA bioequivalence requirements without practicing protected claims.

The principal development risks are:

• Failure to match early methylphenidate exposure
• Excessive variability between fed and fasted states
• Inability to reproduce the sprinkle profile
• Dose dumping under altered-pH conditions
• Inconsistent release across strengths
• Taste or mouthfeel problems after sprinkling
• Stability changes caused by moisture ingress
• Difficulty scaling coating operations

A generic product may need comparative dissolution across multiple pH conditions, alcohol concentrations, agitation rates, and mechanical stress conditions. The reference product’s multiparticulate structure makes simple single-point dissolution matching inadequate.

How does ADHANSIA XR compare with competing methylphenidate products?

Product	Active ingredient	Delivery design	Commercial implication
ADHANSIA XR	Methylphenidate HCl	Multiparticulate immediate-release and extended-release beads	High process complexity; capsule-sprinkle option
CONCERTA	Methylphenidate HCl	Osmotic extended-release tablet	Distinct tablet technology and patent history
RITALIN LA	Methylphenidate HCl	Biphasic bead system	Closest broad technical comparison
FOCALIN XR	Dexmethylphenidate HCl	Biphasic extended-release beads	Different active ingredient and stereochemistry
Quillivant XR	Methylphenidate HCl	Extended-release oral suspension	Liquid formulation and excipient risks
Jornay PM	Methylphenidate HCl	Delayed and extended-release capsule	Different dosing time and release objectives

ADHANSIA XR competes on once-daily delivery and administration flexibility. Its multiparticulate design is technically closer to bead-based products such as RITALIN LA than to osmotic tablets such as CONCERTA. The product’s commercial weakness is manufacturing complexity combined with limited current market presence.

What is the FDA regulatory status of ADHANSIA XR?

ADHANSIA XR was approved under NDA 211125 in 2019. The product’s current marketing status should be distinguished from its approval status. FDA approval does not guarantee ongoing commercial distribution, and a product can remain listed in FDA databases while having limited or no active supply.[1]

For excipient and generic strategy, the relevant regulatory documents are:

• FDA prescribing information
• Drugs@FDA approval history
• Orange Book product and patent listings
• DailyMed labeling
• FDA inactive-ingredient information
• Any FDA notices concerning discontinuation or marketing status

A discontinued or commercially inactive reference product can still retain regulatory importance if FDA recognizes it as the reference listed drug for ANDA purposes. That distinction has direct implications for generic development and reference-product sourcing.

How strong is the ADHANSIA XR formulation estate?

The formulation estate is technically meaningful but likely depends on claim scope and prosecution history. The strongest potential claims would cover the interaction of:

• Bead architecture
• Release-fraction ratio
• Coating composition
• Dissolution profile
• Pharmacokinetic performance
• Administration by sprinkling

The weakest claims would be broad claims directed only to conventional excipients or routine capsule components. Common excipient combinations are vulnerable to obviousness challenges unless linked to an unexpected release profile or demonstrated manufacturing advantage.

From a business perspective, the estate should be assessed through claim-chart analysis, not by counting patent families. A small number of narrow, unexpired patents can create more launch risk than a larger number of expired or redundant filings.

What revenue and licensing opportunities remain?

ADHANSIA XR’s opportunity is more likely to come from IP and technology transactions than from large-scale branded sales. Potential counterparties include:

• Generic pharmaceutical companies seeking a multiparticulate methylphenidate platform
• Contract development and manufacturing organizations with fluid-bed coating capacity
• Excipient suppliers with controlled-release polymer portfolios
• Specialty ADHD companies seeking a capsule-sprinkle product
• Regional licensees in markets where methylphenidate demand remains strong
• Manufacturers seeking a differentiated alternative to tablet-based products

The most defensible licensing asset would be a validated multiparticulate platform with reproducible dissolution and scalable coating economics. The active ingredient is off-patent in principle, so commercial value must come from formulation performance, regulatory readiness, manufacturing know-how, or market access.

Key Takeaways

• ADHANSIA XR is a multiparticulate extended-release methylphenidate capsule approved by FDA in 2019.
• Ethylcellulose, plasticizers, sugar spheres, and drug-layering excipients are central to product performance.
• The main technical barrier is reproducing the combined immediate-release and extended-release profile.
• The product is exposed to generic competition, not biosimilar competition.
• A precise generic launch date requires current Orange Book, patent, and litigation review.
• Excipient suppliers have opportunities in controlled-release polymers, inert cores, plasticizers, capsule shells, and process-control materials.
• The strongest commercial asset is the formulation and manufacturing platform, not the individual inactive ingredients.
• Licensing value depends on validated scale-up, dissolution similarity, sprinkle performance, and freedom to operate.

FAQs

Can ADHANSIA XR beads be reformulated into a tablet?

Yes, but a tablet would represent a different delivery architecture and could raise bioequivalence, patent, and administration issues. A tablet design would need to reproduce the reference product’s clinically relevant exposure profile.

Is ethylcellulose mandatory for an ADHANSIA XR generic?

No. A generic applicant may use another release-controlling polymer if the product satisfies FDA requirements and avoids valid patent claims. Substitution would require extensive dissolution and pharmacokinetic development.

Does sprinkling ADHANSIA XR create a separate formulation patent risk?

Potentially. Claims may cover the dosage form, bead integrity, or administration method. Sprinkle performance should be reviewed separately from intact-capsule administration.

Can a company use the same inactive ingredients as ADHANSIA XR?

Yes, common excipients are generally available for use, subject to regulatory compliance and patent analysis. Using the same excipients does not automatically establish infringement or bioequivalence.

What manufacturing equipment is required for an ADHANSIA XR-type product?

The process typically requires fluid-bed or equivalent equipment for drug layering and polymer coating, along with particle-size classification, blending, encapsulation, and dissolution-control capabilities.

References

1. U.S. Food and Drug Administration. (2019). ADHANSIA XR prescribing information. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211125s000lbl.pdf

2. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (n.d.). ANDA submissions: Patent certifications and related provisions. FDA. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/abbreviated-new-drug-application-anda-forms-and-instructions